The common form of hereditary hemochromatosis — HFE-related, or type 1 — is autosomal recessive. You need two faulty copies of the HFE gene, one from each parent, to be at meaningful risk. One copy makes you a carrier.
But "hemochromatosis" is an umbrella term, and one of the rarer forms underneath it — type 4, or ferroportin disease — is autosomal dominant. That's why you'll find conflicting answers online. Both are right; they're describing different genes.
What "autosomal recessive" actually means
Every gene comes in two copies — one inherited from each biological parent. HFE sits on chromosome 6, which is an autosome (a non-sex chromosome), so it's inherited the same way regardless of whether you're male or female.
Recessive means one working copy is enough. The HFE protein helps regulate hepcidin, the hormone that tells your gut how much iron to absorb. If you have one intact copy, it does the job. Iron absorption stays roughly normal.
It's only when both copies carry a disruptive variant that hepcidin signalling drops far enough for your intestine to keep absorbing iron when your body doesn't need it. Iron has no active excretion route in humans — you lose a bit through shed skin cells, gut lining and, for menstruating people, blood. So the surplus accumulates, decade after decade, in the liver, heart, pancreas and joints.
The two variants that matter most are named for the amino acid changes they cause:
- C282Y (
c.845G>A) — the serious one. Two copies of this is the classic hemochromatosis genotype. - H63D (
c.187C>G) — far more common, far milder. On its own it rarely causes iron overload. - S65C — a third, uncommon variant with modest effect.
Together, C282Y and H63D account for roughly 87% of hereditary hemochromatosis in European populations, and C282Y homozygosity alone explains the large majority of clinically significant cases.
The inheritance maths, in a grid
If both parents are carriers — each has one C282Y copy and one normal copy — here's how the dice fall for each pregnancy. Read the parent genotypes along the top and side; Y is the C282Y variant, N is a normal copy.
unaffected
carrier
carrier
homozygous
So for two carrier parents, each child has a 25% chance of inheriting two variant copies, a 50% chance of being a carrier like their parents, and a 25% chance of inheriting neither.
Those odds reset with every pregnancy. Three children with two normal copies does not make the fourth more likely to be homozygous — the coin has no memory.
Two other combinations come up often in real families:
- One homozygous parent × one carrier parent: 50% homozygous, 50% carrier. No child escapes carrying at least one copy.
- One homozygous parent × one non-carrier parent: every child is a carrier, and none will be homozygous. This is why testing the unaffected partner is so useful — a negative result there effectively takes the children off the worry list.
The base rates matter here too. Around 10–15% of people of northern European ancestry carry one copy of C282Y, and roughly 1 in 150 carry two. That makes it the most common inherited condition in that population — more common than cystic fibrosis by an order of magnitude. It is correspondingly rare in East Asian, sub-Saharan African and Indigenous American ancestries.
Your HFE genotype is already in your genome — if you sequence it
Dante Labs' whole genome sequencing reads C282Y, H63D and S65C alongside every other variant in your DNA, rather than the handful a targeted panel checks. If iron runs in your family, it answers the inheritance question directly instead of by inference.
See Dante Labs WGS → Code GENOME — 10% offAffiliate link. A genomic test is not a clinical diagnosis — confirm findings with your doctor.
Two faulty copies doesn't mean you'll get sick
This is the part most inheritance explainers skip, and it's the part that matters most if you've just had a result come back.
Genetics has a concept called penetrance — the share of people with a genotype who actually develop the associated condition. For C282Y homozygosity, penetrance is incomplete, and researchers have argued about how incomplete for twenty-five years.
| Estimate | What it measured | Figure |
|---|---|---|
| Meta-analysis of 16 studies | Clinical penetrance of C282Y homozygosity | ~14% |
| UK Biobank cohort | Expected to be diagnosed with haemochromatosis by age 80 | 56% of men, 41% of women |
| Review of empirical sources | Lifetime risk of severe liver disease in male homozygotes, untreated | roughly 1 in 10 |
| Population screening studies | Biochemical penetrance (raised ferritin or transferrin saturation) | often 50%+ |
Those numbers look contradictory. They aren't — they're measuring different things. The 14% meta-analysis figure reflects clinical disease across mixed study designs; the much higher UK Biobank estimate follows people to age 80 and counts any haemochromatosis diagnosis. Abnormal blood iron markers are common; full-blown organ damage is much less so.
Three consistent patterns emerge across all of them:
- Men are affected far more often than women. Menstruation and pregnancy shed iron for decades, which is a natural brake. Risk in women rises after menopause.
- It builds slowly. Symptoms typically surface in the 40s to 60s, not childhood. That's a long window in which to catch it.
- Modifiers matter. Alcohol intake, other liver disease, and additional genetic factors all shift the odds. One twin study found HFE variants explained under 5% of the variation in ferritin levels — other genes are doing a lot of work we haven't fully mapped.
The upside of a scary genotype. Hemochromatosis is one of the most treatable serious genetic conditions there is. The treatment is phlebotomy — donating blood on a schedule. Caught before organ damage sets in, life expectancy is normal. The tragedy of this condition is almost entirely a tragedy of late diagnosis, and inheritance information is exactly what pulls diagnosis earlier.
The dominant exception: ferroportin disease
If a doctor or a relative has told you their iron condition is dominantly inherited, they may well be right — just about a different gene.
Type 4 hemochromatosis, better known as ferroportin disease, is caused by variants in SLC40A1 and is inherited in an autosomal dominant pattern. One faulty copy is enough. That means:
- An affected parent has a 50% chance of passing it to each child.
- It usually appears in successive generations — parent, child, grandchild — rather than skipping around as recessive conditions do.
- There is no carrier state in the usual sense.
SLC40A1 encodes ferroportin, the only known iron export protein in mammals, and it is considered the second most common cause of inherited iron overload after HFE — though still far rarer. It also behaves differently in the blood: the classic loss-of-function form produces high ferritin with normal or low transferrin saturation, which is close to the inverse of the HFE pattern and a common source of diagnostic confusion.
A targeted HFE panel will not detect it. That's one of the practical arguments for broader sequencing when iron overload is real but the HFE result comes back unremarkable.
All five types, side by side
| Type | Gene | Inheritance | Notes |
|---|---|---|---|
| Type 1 (classic) | HFE | Autosomal recessive | By far the most common; C282Y homozygosity |
| Type 2A (juvenile) | HJV | Autosomal recessive | Rare, severe, presents in teens and 20s |
| Type 2B (juvenile) | HAMP | Autosomal recessive | Rare; affects hepcidin directly |
| Type 3 | TFR2 | Autosomal recessive | Rare; resembles type 1 but earlier onset |
| Type 4 (ferroportin) | SLC40A1 | Autosomal dominant | High ferritin, often normal transferrin saturation |
Note that the juvenile forms are recessive too — so a young person with severe iron overload and no family history is not evidence against recessive inheritance. Recessive conditions routinely appear to come out of nowhere, because carriers are silent.
What this means for your relatives
If someone in your family has been diagnosed with HFE hemochromatosis, the inheritance pattern tells you exactly who to prioritise. This is called cascade testing, and it is widely endorsed even by guideline bodies that are sceptical of population-wide screening.
- Siblings are highest priority. Full siblings of a homozygous person have a 1-in-4 chance of being homozygous themselves — the single highest-yield group to test.
- Parents and children of a homozygous person are, at minimum, obligate carriers, and may be homozygous depending on the other parent's genotype.
- Test the spouse before the kids. If the unaffected partner carries no variant, the children can only be carriers. It's one test that can substitute for several.
- Adults, not infants. Iron accumulates over decades. Guidelines generally direct screening at first-degree relatives from around age 20 rather than in childhood.
The practical sequence in most health systems is iron studies first, genotyping second: European guidelines advise measuring transferrin saturation and ferritin, then genotyping when those are abnormal. We cover that sequence, and what each genotype result means, in our guide to the HFE gene test.
Recessive conditions hide until someone looks
Carrier status is invisible — no symptoms, normal bloods, nothing to notice. Whole genome sequencing surfaces HFE, SLC40A1, HJV, HAMP and TFR2 together, so you're not testing one gene and hoping it was the right one.
Explore whole genome sequencing → Code GENOME — 10% offAffiliate link. Discuss any actionable finding with a clinician or genetic counsellor.
Common questions
Is hemochromatosis dominant or recessive?
The common form — HFE-related type 1 hemochromatosis — is autosomal recessive, requiring two variant copies. Type 4 hemochromatosis, or ferroportin disease, caused by SLC40A1 variants, is autosomal dominant and needs only one. The remaining rare types (2A, 2B and 3) are all recessive.
Can hemochromatosis skip a generation?
Yes, and it commonly appears to. Because HFE hemochromatosis is recessive, carriers pass the variant on without ever showing symptoms. A condition can travel silently through several generations of carriers before two of them have a child together. Dominant ferroportin disease, by contrast, usually appears in every generation.
If both my parents are carriers, will I definitely have it?
No. Each child of two carriers has a 25% chance of inheriting both variant copies, a 50% chance of being a carrier, and a 25% chance of inheriting neither. And even inheriting two copies doesn't guarantee illness — penetrance is incomplete, and many homozygotes never develop clinically significant iron overload.
Does hemochromatosis affect men and women differently?
The inheritance is identical — HFE is on chromosome 6, an autosome, so sex plays no role in who inherits what. But the expression differs substantially. Menstruation and pregnancy remove iron, which delays accumulation in women by years or decades. Studies consistently find higher rates of iron overload in male homozygotes, with risk in women rising after menopause.
Is being a carrier of one C282Y copy dangerous?
For nearly all carriers, no. One working copy of HFE is sufficient to regulate iron absorption normally, and controlled studies have found that C282Y heterozygotes do not absorb dietary iron more efficiently than people with two normal copies. Carrier status matters mainly for family planning and for interpreting relatives' results. We go into detail in our guide to carrier status.
Can I have hemochromatosis with only one HFE variant?
Clinically significant iron overload from a single HFE variant is uncommon. If your iron markers are genuinely high and you carry only one copy, doctors typically look for another explanation — metabolic syndrome, fatty liver, alcohol, chronic inflammation, or a variant in a different iron gene such as SLC40A1 that a standard HFE panel wouldn't have checked.
Sources
- Pathophysiological consequences and benefits of HFE mutations: 20 years of research
- Genetic and lifestyle modifiers of haemochromatosis-related outcomes in HFE C282Y homozygotes, UK Biobank
- Clinical penetrance of C282Y homozygous HFE haemochromatosis
- Type 4 haemochromatosis (ferroportin disease), Haemochromatosis UK
- Disease-causing mutations in the ferroportin 1 (SLC40A1) gene
- EASL Clinical Practice Guidelines on haemochromatosis
- Hemochromatosis mutations, dementia and brain iron deposition (cohort prevalence data)
Medical disclaimer. GenomeTesting.org publishes educational content about genetics and consumer genomic testing. Nothing here is medical advice, a diagnosis, or a substitute for care from a qualified clinician or genetic counsellor. Decisions about testing, treatment, or interpreting your own results should be made with a healthcare professional who can see your full history.
Affiliate disclosure. Some links on this page are affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes which products we recommend or what we say about them.